NCT06173505
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06173505
Title Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Xencor, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | GRC | ESP | BEL

Facility Status City State Zip Country Details
Palo Verde Cancer Specialists Glendale Arizona 85304 United States Details
Eastern Connecticut Hematology and Oncology Associates Norwich Connecticut 06360 United States Details
Hematology Associates of Fredericksburg Fredericksburg Virginia 22408 United States Details
Jessa Ziekenhuis - Campus Virga Jesse Hasselt 3500 Belgium Details
St. Lukes (Agios Loucas) Hospital Thessaloniki 552 36 Greece Details
Hospital Sultan Ismail Johor Bahru 81100 Malaysia Details
Hospital Umum Sarawak Kuching 93586 Malaysia Details
Institut Kanser Negara Putrajaya 62250 Malaysia Details
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Amsterdam North Holland 1066 CX Netherlands Details
ULS do Alto Ave, EPE - Hospital da Senhora da Oliveira Guimarães Guimarães 4835-044 Portugal Details
NEXT Oncology-Hospital Quirónsalud Barcelona Barcelona 08023 Spain Details
Hospital Clinic i Provincial de Barcelona Barcelona 08036 Spain Details
Institut Català d'Oncolgia de Girona Girona 17007 Spain Details
Hospital Clínico San Carlos Madrid 28040 Spain Details
Hospital Universitario La Paz Madrid 28046 Spain Details
Changhua Christian Hospital Changhua 500 Taiwan Details
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City 807 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field